[8] Additionally, in animals, there is no metabolic pathway that allows the production of pyruvate from acetyl-CoA, due to the irreversibility of the reaction catalyzed by the pyruvate dehydrogenase complex, namely, the oxidative decarboxylation of pyruvate to acetyl-CoA
doi: 10.18632/oncotarget.2386 182 MangoniMSottiliMGeriniCFucciRPiniACalosiLet al
Injectables offer a workaround that delivers nutrients where theyre needed without relying on the gut
Together, they promote a more youthful, resilient complexionleaving skin supple, refreshed, and glowing after consistent use

Get the Injury, Joint & Recovery Blueprint *Educational only No protocols Written by clinicians* When to Use BPC-157 + TB-500 This blend is ideal for a range of patients and scenarios, including: Athletes looking to recover from training faster Post-surgical patients needing accelerated healing Individuals with tendinopathy , ligament sprains , or joint instability Chronic pain sufferers seeking regenerative alternatives Patients with gut inflammation or leaky gut (BPC-157 has GI-healing properties) People with connective tissue disorders or injury-prone joints Individuals experiencing inflammatory joint conditions (such as arthritis) Expected Results While every patient responds differently, many experience: Reduced pain and inflammation within 12 weeks Enhanced range of motion and tissue resilience Accelerated recovery time from injuries or surgeries Improved mobility and flexibility Reduced gut permeability and inflammation (via BPC-157) Peak results are typically seen 48 weeks into therapy, depending on severity and dosing
